Moreover, compared with first-generation EGFR-TKIs, osimertinib exhibits higher efficacy and a lower toxicity profile, as well as longer PFS and overall survival in treatment-naïve patients with EGFR-mutant-advanced NSCLC [6,7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.